Prior treatment can permanently or temporarily exclude participation. Give the study team a complete treatment history and obtain written pre-screening before changing any current therapy.
What this means in real life
Prior treatment can affect another trial because of biological interaction, safety, immune response or the need to measure an unconfounded effect. AAV gene therapy is especially important because antibodies and prior exposure may permanently exclude another AAV study. Exon-skipping medicines, givinostat, steroids and other investigational agents may require stable dosing or a protocol-defined washout.
Never stop an approved or beneficial treatment just to chase theoretical eligibility. First give the study team a complete history—including dates, doses, trial/placebo uncertainty, gene therapy, biopsies and serious adverse events—and request written prescreening. Then the treating DMD clinician should assess the risk of changing care.
Eligibility rules differ across protocols and can change through amendments. A person excluded from one study may qualify for another, and a positive antibody test for one vector or assay may not answer every future study question.
A practical checklist
- ✓
Maintain a lifetime treatment and research timeline.
- ✓
Disclose all approved, off-label and investigational exposures.
- ✓
Ask whether exclusion is temporary, permanent or product-specific.
- ✓
Get written prescreening before any washout.
- ✓
Coordinate every treatment change between the trial and usual-care teams.
Questions to bring with you
Use these at the clinic, school meeting, equipment evaluation, program interview or benefits call. Write down the answers and who owns the next step.
- Which prior exposure creates the conflict, and why?
- Is a washout scientifically and medically reasonable?
- Would stopping current therapy risk irreversible decline?
- Does prior gene therapy exclude this vector, product or all AAV trials?
- Could another study design fit without changing care?
Important context
Individual needs, eligibility and safety can differ. Confirm the plan with the relevant Duchenne-experienced clinician, therapist, school team or program before acting.
Sources used for this guide
Direct links are included so families can check the original guidance and bring it to qualified professionals.
Content review: July 18, 2026. Medical labels, trials, benefits and programs can change after publication.
Did this article answer the question?
A thumbs-down sends the article to the private administrator dashboard for review.